Heat Shock Protein 90 Versus Conventional Growth Factors in Acute and Diabetic Wound Healing
Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes in the United States of America. The number of diabetic foot ulcer-caused lower limb amputations is approaching 100,000/year, a rapid increase due to an aging population and the rising incidence of obesity. Cost-effect treatments are currently limited. For decades, the conventional wisdom is that growth factors constitute the driving forces of wound healing. Therefore, more than 30 growth factors have been extensively studied in animal models and a dozen of these growth factors have been subjected to clinical trials. Only PDGF-BB received the US FDA approval for treatment of diabetic ulcers in 1997. However, the modest efficacy, high cost and risks of causing cancer by PDGF-BB (becaplermin gel) have limited its use in clinical practice. This reality continues to be overlooked or ignored. An unconventional wound-healing molecule, extracellular heat shock protein-90alpha (eHsp90α), has recently been reported. Unlike restricted cell type specificity of PDGF-BB, eHsp90α is a common pro-motility factor of all skin cells, eHsp90α also overrides TGFβ inhibition and hyperglycemia. Topical application of eHsp90α accelerated both acute and diabetic wound closure far more effectively than PDGF-BB. We discuss what makes Hsp90α superior to conventional growth factors in wound healing.
KeywordsWound Healing Transform Growth Factor Dermal Fibroblast Wound Edge Dermal Cell
This study was supported by NIH grant GM/AR066193-01 (to W. L.) and AR46538 (to D. T. W.).
- Alvarez OM, Meehan M, Ennis W, Thomas DR, Ferris FD, Kennedy KL, Rogers R, Bradley M, Baker JJ, Fernandez-Obregon A, Rodeheaver G (2002) Chronic wounds: palliative management for the frail population. Wounds 14(p Suppl):713–732Google Scholar
- Cheng CF et al (2011) A fragment of secreted from Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice. J Clin Invest 121:4348–4361Google Scholar
- Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507–514Google Scholar
- Gao Z, Sasaoka T, Fujimori T, Oya T, Ishii Y, Sabit H, Kawaguchi M, Kurotaki Y, Naito M, Wada T, Ishizawa S, Kobayashi M, Nabeshima Y, Sasahara M (2005) Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem 280:9375–9389PubMedCrossRefGoogle Scholar
- Habich C, Baumgart K, Kolb H, Burkart V (2000) The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol 168:569–576Google Scholar
- Kuroita TH, Tachibana H, Ohashi S, Shirahata H, Murakami (1992) Growth stimulating activity of heat shock protein 90 alpha to lymphoid cell lines in serum-free medium. Cytotechnology 8(1992):109–117Google Scholar
- Li W, Sahu D, Tsen F (2012) Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta 1823:730–741Google Scholar
- Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A (1992) Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair. Am J Pathol 140:1375–1388PubMedGoogle Scholar
- Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH (1999) Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 7:335–346PubMedCrossRefGoogle Scholar
- Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169:3978–3986PubMedGoogle Scholar
- Wieman TJ, Smiell JM, Su Y (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21:822–827PubMedCrossRefGoogle Scholar
- Yu X, Harris SL, Levine AJ (2006) The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 66:4795–4801Google Scholar